SBFI-26
Modify Date: 2024-01-09 17:27:23
SBFI-26 structure
|
Common Name | SBFI-26 | ||
|---|---|---|---|---|
| CAS Number | 1541207-06-0 | Molecular Weight | 422.47 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C28H22O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SBFI-26SBFI-26 is a selective and competitive inhibitor of fatty acid binding proteins FABP5 and FABP7, with Kis of 0.9 µM and 0.4 µM for FABP5 and FABP7, respectively. SBFI-26 produces anti-nociceptive and anti-inflammatory effects[1][2]. |
| Name | SBFI-26 |
|---|
| Description | SBFI-26 is a selective and competitive inhibitor of fatty acid binding proteins FABP5 and FABP7, with Kis of 0.9 µM and 0.4 µM for FABP5 and FABP7, respectively. SBFI-26 produces anti-nociceptive and anti-inflammatory effects[1][2]. |
|---|---|
| Related Catalog | |
| Target |
Ki: 0.9 μM (FABP5), 0.4 µM (FABP7)[1][2] |
| In Vitro | SBFI-26 binds to the canonical ligand-binding pocket of FABP5[1]. SBFI-26 significantly inhibits cellular AEA accumulation[2]. |
| In Vivo | SBFI-26 (20 mg/kg, i.p.) significantly reduces carrageenan-induced thermal hyperalgesia and paw edema[2]. SBFI-26 produces antinociceptive and anti-inflammatory effects in mice[2]. Animal Model: Mice[2] Dosage: 20 mg/kg Administration: Intraperitoneal injection Result: Significantly reduced carrageenan-induced thermal hyperalgesia and paw edema. |
| References |
| Molecular Formula | C28H22O4 |
|---|---|
| Molecular Weight | 422.47 |